Keyphrases
Acute-on-chronic Liver Failure
7%
Ascites
20%
Atorvastatin
7%
Bacterial Translocation
5%
Beta-blockers
11%
Chronic Liver Disease
6%
Cirrhosis
100%
Confidence Interval
6%
COVID-19
7%
Decompensated Cirrhosis
26%
Disease Progression
6%
Hepatic Encephalopathy
19%
Hospitalization
8%
Inflammation
10%
Inflammation Markers
8%
Large-volume Paracentesis
5%
Liver
10%
Liver Cirrhosis
19%
Metabolic-associated Fatty Liver Disease (MAFLD)
7%
PleurX
6%
Portal Hypertension
18%
Portal Pressure
6%
Prospective Cohort Study
5%
Randomized Clinical Trial
6%
Randomized Placebo-controlled Trial
15%
Refractory Ascites
9%
Rifaximin
26%
Systematic Meta-analysis
7%
Systemic Inflammation
7%
Treatment Complications
5%
Umbilical Hernia Repair
9%
Medicine and Dentistry
Ammonium
5%
Ascites
20%
Bacterial Translocation
5%
Beta Adrenergic Receptor Blocking
6%
Beta Adrenergic Receptor Blocking Agent
8%
Chronic Liver Disease
6%
Cohort Analysis
8%
Complication of Treatment
5%
COVID-19
7%
Decompensated Liver Cirrhosis
18%
Disease Exacerbation
5%
Hemodynamic
8%
Hepatic Encephalopathy
19%
Hepatocellular Carcinoma
5%
Hernioplasty
10%
Liver Cirrhosis
87%
Liver Disease
7%
Meta-Analysis
8%
Paracentesis
6%
Placebo
12%
Portal Hypertension
15%
Portal Venous Pressure
5%
Randomized Controlled Trial
5%
Rifaximin
19%
Spontaneous Bacterial Peritonitis
6%
Symptom
6%
Systematic Review
11%
Umbilical Hernia
11%
Pharmacology, Toxicology and Pharmaceutical Science
Acute on Chronic Liver Failure
7%
Ammonium
7%
Anti-Inflammatory Drug
5%
Ascites
16%
Beta Adrenergic Receptor Blocking Agent
12%
Decompensated Liver Cirrhosis
10%
Disease
7%
Fibrosis
5%
Hepatic Encephalopathy
19%
Inflammation
19%
Liver Cirrhosis
74%
Liver Disease
10%
Placebo
13%
Portal Hypertension
17%
Rifaximin
26%